Özlem Türeci, M.D.

Özlem Türeci is an M.D. with over 20 years’ experience in cancer research. Her focus is the identification of immunotherapeutic drug targets and development of antibody as well as vaccine based therapies for non-hematological cancers.

She is co-founder of Ganymed Pharmaceuticals AG, a clinical stage biotech company developing ideal antibody drugs which was sold to Astellas in October 2016. She is Chairman and co-initiator of the Ci3 Cluster of Individualized ImmunIntervention (Ci3) e.V.. She is an executive board member of the Association for Cancer Immunotherapy (CIMT). Özlem is the author of over 75 peer-reviewed publications with a cumulative citation index of 7000 and inventor on 530 patents and patent applications.